KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.
Esophageal Squamous Cell Carcinoma
DRUG: KN046|RADIATION: palliative radiotherapy|DRUG: KN046
dose-limiting toxicity KN046, 28 days after first dose|6-month progression free survival rate assessed by investigator based on RECIST 1.1, 6 months after first dose|Objective response rate assessed by investigator based on RECIST 1.1, 2 years
This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.